Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in Von Willebrand Disease Type 2B
NCT00694785Phase 2Withdrawn
- Sponsor
- Archemix Corp.
- Start
- Oct 2008
- Primary completion
- Jun 2009
- Modality
- RNA Aptamers, Recombinant Proteins and Enzymes, DNA Aptamers
01
Overview
A Phase 2 trial of egaptivon pegol in von Willebrand disease type 2B (VWD2B), sponsored by Archemix Corp.. Planned start Oct 2008; status: withdrawn.
02
Drugs
egaptivon pegol
03
Conditions
von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on NCT00694785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694785.